Ashvattha Therapeutics Announces Collaboration With Stanford University for Preclinical Development of a Novel Neuroimaging Agent, OP-801

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced the initiation of a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine l

Click to view original post